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    Pathological cascade and structural magnetic 
resonance imaging
Alzheimer’s disease (AD) is a multifaceted disease in 
which cumulative pathological brain insults result in 
progressive cognitive decline that ultimately leads to 
dementia. Amyloid plaques, neuroﬁ  brillary tangles (NFTs), 
neurodegeneration, and inﬂ   ammation are the well-
established pathological hallmarks of AD. A plausible 
model for the development of AD posits that amyloid 
deposition occurs early in the process but by itself does 
not directly cause clinical symptoms [1,2]. Neuronal and 
synaptic losses appear to be key determinants of 
cognitive impairment in AD [3,4]. If neuronal loss leads 
to cerebral atrophy (as is likely), then it can be expected 
that cognitive decline and atrophy will be closely asso-
ciated. On the basis of this evidence, it has been hypothe-
sized that AD pathological cascade is a two-stage process 
in which amyloidosis and neuronal pathology (tauopathy, 
neuronal injury, and neurodegeneration) are largely 
sequential rather than simultaneous processes [1,5,6]. 
Th   ere is also suﬃ   cient literature to support the fact that 
atrophy of the brain structures or neurodegeneration is 
the most proximate substrate of cognitive impairment in 
AD [2,7-9]. Th  is hypothesis of a sequential model was 
proposed by Jack and colleagues [6] on the basis of 
biomarker data and is adapted and illustrated in Figure 1.   
Owing to the close relationship between neuro  degenera-
tion and cognition (as illustrated in Figure 1), atrophy 
measured on structural magnetic resonance imaging 
(sMRI) is a powerful AD biomarker.
sMRI measures brain morphometry and therefore can 
capture gray matter atrophy related to the loss of 
neurons, synapses, and dendritic de-arborization that 
occurs on a microscopic level in AD; white matter 
atrophy related to the loss of structural integrity of white 
matter tracts, presumably resulting from demyelination 
and dying back of axonal processes; and ex vacuo 
expansion of cerebrospinal ﬂ  uid (CSF) spaces. Since there 
is a signiﬁ  cant negative correlation between NFT density 
and neuronal counts [10], sMRI indirectly reﬂ  ects NFT 
density. It has been shown that neuronal loss correlates 
with but exceeds NFT density in AD and is related 
directly to impaired cognitive function [10]. Neuronal 
loss also correlates with Braak NFT stage and quantitative 
NFT burden, validating sMRI as an AD biomarker 
[11-13]. Th  is review provides a summary of the role of 
sMRI as an AD biomarker. First, we begin with the most 
commonly used methods to extract information from 
sMRI images, then we discuss the diﬀ  erent roles in which 
sMRI can be used as a biomarker in AD, and ﬁ  nally we 
compare the performance of sMRI to that of other major 
AD biomarkers.
Extracting information from structural magnetic 
resonance imaging
Given the large amount of data present in a three-
dimensional (3D) sMRI scan, several diﬀ  erent methods 
are employed to condense atrophy information in each 
patient’s scan or assess atrophy over multiple scans of the 
same individual. Th   e pattern of neurodegeneration seen 
using sMRI is similar to the progression of neuroﬁ  brillary 
pathology as described by Braak and Braak [14]. Th  e 
disease usually begins and is ultimately most severe in 
the medial temporal lobe, particularly the entorhinal 
cortex and hippocampus. Later (that is, when subjects 
are in the clinical mild cognitive impairment [MCI] 
phase), the disease spreads to the basal temporal lobe and 
paralimbic cortical areas such as the posterior cingulate 
gyrus and precuneus. Th   e onset of dementia is due to the 
spread of degenerative atrophy to multimodal association 
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© 2010 BioMed Central Ltdneo  cor  tices. Basal forebrain and the dorsal ponto-
mesencephalic areas are also involved. However, unusual 
variants that do not follow this particular pattern are 
increasingly recognized. Furthermore, other limbic lobe 
structures such as posterior cingulate seem to be involved 
early and consistently in AD. Figure 2 shows typical MRI 
scans in cognitively normal (CN) subjects and in patients 
with MCI or AD. As can been seen in the ﬁ  gure, there is 
increasing medial temporal atrophy (speciﬁ  cally,  the 
hippocampus and ventricular enlargement) in MCI and 
AD when compared with CN. Here, we present a brief 
survey of methods to extract or visualize this information 
(or both) from 3D sMRI scans of cross-sectional and 
longitudinal studies.
Cross-sectional methods
When changes in diﬀ   erent individuals are measured 
cross-sectionally, the most widely used summary 
measures from sMRI are the following:
1. Visual assessment of scans
Often, visual assessment of the degree of atrophy in the 
medial temporal lobe is used as a metric to measure 
disease [15,16]. Visual assessment oﬀ   ers a fast and 
eﬃ   cient way to assess MRI scans but does not capture 
the ﬁ  ne incremental grades of atrophy.
2. Quantitative region of interest-based techniques 
or volumetry
Volumetry is the most common cross-sectional quanti-
tative metric used in AD. Although traditionally manual 
tracing of volumes was used, the increase in compu-
tational power has led to the development of automated 
techniques.
2a. Manual tracing
Tracing and quantifying the volume of medial temporal 
lobe structures (for example, the hippocampus or ento-
rhinal cortex) or posterior cingulate have been tradition-
ally employed in AD and provide an accurate quantitative 
measure of atrophy [17]. However, manual measurements 
can be tedious and time-consuming.
2b. Automated and semi-automated techniques
In the recent past, methods have been proposed to 
automatically parcellate gray matter density or cortical 
surfaces into regions of interest. Th  ese cortical surfaces 
are used to compute global as well as a regional cortical 
thickness (that is, combined thickness of the layers in the 
cerebral cortex). Because automated and semi-automated 
techniques do not require signiﬁ   cant manual inter-
vention, they are extremely useful for large-scale studies.
An advantage of volumetry, such as measuring the 
hippocampus, is that the measurements describe a 
known anatomic structure that (in the case of the hippo-
campus) is closely related to the pathological expression 
of the disease and is also functionally related to one of the 
cardinal early clinical symptoms – memory impairment. 
However, the disadvantage of using a single region of 
interest to consolidate 3D information as a disease metric 
is that it is spatially limited and does not make use of all 
of the available information in a 3D sMRI.
3. Quantitative voxel-based
Th   ese methods assess atrophy over the entire 3D sMRI scan.
3a. Voxel-based analytic techniques
Methods such as voxel-based morphometry (VBM) [18] 
have been developed to provide a powerful way to test for 
Figure 1. Proposed Alzheimer’s disease pathological cascade based on biomarkers. MCI, mild cognitive impairment. Modifi  ed and 
reproduced with permission from [6].
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scans of diseased group versus normal controls. Th  e 
typical atrophy patterns seen in subjects with AD or MCI 
are similar to those of the Braak neuroﬁ  brillary staging 
described above. Although VBM enables visualization of 
the pattern of neurodegeneration due to disease, the 
statistical testing portion of VBM is designed only to test 
for group-wise diﬀ   erences between two groups of 
subjects and cannot provide a summary measure for each 
subject, and this makes it inapplicable to diagnosis in 
individual subjects.
3b. Automated individual subject diagnosis
Several investigators have recently turned their attention 
to multivariate analysis and machine learning-based 
algorithms that use the entire 3D sMRI data to form a 
disease model against which individual subjects may be 
compared. Th   ese scores typically are computed for each 
new incoming scan (that is, test scan) on the basis of the 
degree and the pattern of atrophy in comparison with the 
scans of a large database of well-characterized AD and 
cognitively normal subjects [19-22].
Longitudinal methods
Because accelerating tissue loss is a hallmark of neuro-
degenerative disease, serial sMRI scans often are 
analyzed to measure disease progression. Even though 
cross-sectional measures can be employed to obtain a 
summary measure from sMRI at every time point, these 
measures have unnecessary variability due to inherent 
noise associated with each individual measurement. 
Th  erefore, speciﬁ   c techniques have been developed to 
extract tissue loss information from serial sMRI scans. In 
these techniques, all pairs of sMRI scans are registered to 
each other and brain loss between scans is quantiﬁ  ed and 
this reduces the variability.
Global atrophy quantifi  cation
One of the earliest methods developed to quantify the 
global percentage change in brain volume between two 
scans was boundary shift integral (BSI) [23]. BSI 
determines the total volume through which the surface of 
the brain has moved between scans acquired at two time 
points (that is, the brain volume decreases and the volume 
of the ventricles increases). One of the most sensitive 
global measures for measuring the rates of brain atrophy is 
the ventricular change measure using BSI [24]. Th  is is 
because the ventricular boundary on sMRI (T1-weighted 
images) provides a good contrast for the delineation of the 
ventricular surface with more accuracy when compared 
with brain volume and hippocampal volume.
Tensor-based morphometry
Unlike BSI, which analyzes only spatial shift in the brain 
surfaces, TBM provides a 3D proﬁ  le of voxel-level brain 
degeneration. Here, the term TBM is used to describe 3D 
voxel-based methods that can be employed to observe 
how the disease progresses in the brain as a result of the 
underlying pathological changes [25,26].
Role of structural magnetic resonance imaging in 
Alzheimer’s disease and mild cognitive impairment
In this section, we will brieﬂ  y discuss the diﬀ  erent roles 
in which sMRI can be employed as an AD biomarker. 
When MCI involves primarily memory complaints and 
deﬁ  cits, it is often considered a prodromal stage of AD. 
Here, we will also discuss the role of sMRI in MCI in 
addition to AD.
1. Early diagnosis of Alzheimer’s disease and mild cognitive 
impairment
Th  e typical reductions of hippocampal volume in MCI 
with an average Mini-Mental State Exam (MMSE) score 
Figure 2: Progressive atrophy (medial temporal lobes) in an older cognitively normal (CN) subject, an amnestic mild cognitive 
impairment (aMCI) subject, and an Alzheimer’s disease (AD) subject.
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score of 20 are 20% to 25% [27]. Measuring these signiﬁ  -
cant reductions (due to AD) in the medial temporal lobe 
can be extremely useful for early diagnosis of AD and 
MCI. At present, diagnostic criteria for AD are based on 
the criteria in the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DSM-IV), which are 
based primarily on clinical and psychometric assessment 
and do not use quantitative atrophy information available 
in sMRI scans. However, there is a proposal to add 
reliable biomarkers to the diagnostic criteria [28]. One of 
the suggested features is the volume loss of medial 
temporal structures since measures of sMRI atrophy have 
accuracies of 70% to 90% in AD and 50% to 70% in 
amnestic MCI in distinguishing them from age-matched 
controls [28]. All of the above-mentioned cross-sectional 
methods, except 3a, can be used as diagnostic metrics for 
AD and MCI.
2. Predicting the risk of progression in mild cognitive 
impairment and cognitively normal
Although there is considerable variability of progression 
rates in MCI to AD, it has been observed that an average 
of about 10% to 15% of subjects with MCI, speciﬁ  cally of 
the amnestic type, annually progress to AD [29]. Because 
pathological changes occur before the onset of clinical 
symptoms, biomarkers can aid in the prediction of risk of 
progression in MCI and CN. A recent meta-analysis 
showed that hippocampal volume can detect an average 
of approximately 73% of MCI subjects who progress to 
AD [30]. Several studies using both cross-sectional 
methods 1 and 2 above have shown that atrophy seen on 
MRI can predict the risk of progression to AD with good 
accuracy.
3. Evaluating disease progression
Charting structural changes in the brain over time is 
important in monitoring the progression of the disease 
[31]. Tracking the disease progression is especially 
important in patients with MCI and cognitively normal 
subjects since atrophy rates can predict subsequent 
clinical progression in both groups. Th   e metrics that are 
most often used for evaluating or tracking disease 
progression are increase in ventricular volume and 
decrease in brain volume over time. Th   ese measures are 
more sensitive than cross-sectional measures in captur-
ing changes over time since all scans of the same subject 
are registered together to reduce inter-scan variability.
4. Measuring the effi   cacy of therapeutics
Several investigators have shown that the lower variance 
in the serial sMRI measurements compared with clinical 
measures of cognition and function could permit clinical 
trials to be performed with smaller sample sizes than 
would be possible using traditional clinical instruments 
[32-34]. At present, AD biomarkers have not yet been 
validated as surrogate endpoints for regulatory purposes 
and therefore cannot be used as the primary indicators of 
eﬃ   cacy. However, the impact of interventions on these 
biomarkers has been evaluated in a few trials and was 
found to be potentially useful in capturing the pharma-
codynamic eﬀ  ects. Th  e eﬃ   cacy of donepezil, a cholin-
esterase inhibitor, was evaluated using serial sMRI 
[35,36] and was found to possibly be neuro-protective in 
nature since there was some evidence for decreased 
disease progression on the basis of sMRI trophy. In a 
diﬀ  erent study, it was observed that subjects immunized 
with Aβ antibody responders had a more rapid volume 
loss than placebo patients during a phase IIa immuno-
therapy trial that was prematurely terminated owing to 
meningoencephalitis in a subset of patients [37]. In 
addition to evaluating therapeutic eﬃ   cacy, atrophy on 
sMRI can be used to select at-risk MCI subjects for 
clinical trials. While longitudinal methods are useful for 
testing eﬃ   cacy of therapeutics, cross-sectional methods 
are most suited for sample enrichment.
5. Screening in clinical trials
MRI is routinely used at two stages in clinical trials. Th  e 
ﬁ  rst is screening at baseline for inclusion/exclusion. Th  is 
includes identifying subjects with imaging evidence of 
conditions that are exclusionary (for example, hemi  spheric 
infarction or prior evidence of cerebral hemor  rhage). Also, 
anti-amyloid trials commonly will exclude subjects with 
micro-hemorrhages that exceed a speciﬁ  ed number. Either 
long echo time gradient echo or susceptibility-weighted 
imaging sequences are used for micro-hemorrhage 
identiﬁ  cation. MRI is also used for safety screening during 
the study. Conditions that are of interest are evidence of 
new micro-hemorrhage and vasogenic edema. FLAIR 
(ﬂ   uid-attenuated inversion recovery) and diﬀ  usion 
imaging are used to identify the latter condition.
6. Diff  erential diagnosis of dementia subtypes
Given that pathology does not always map onto the 
clinical expression of the disease and has considerable 
clinical heterogeneity, biomarkers such as sMRI can aid 
in the diﬀ   erential diagnosis of dementia types. Th  e 
absence of signiﬁ  cant medial temporal lobe atrophy in 
dementia with Lewy bodies [38] and vascular dementia 
[39], signiﬁ  cant frontal lobe atrophy in behavioral variant 
fronto-temporal dementia [40], or pronounced asym-
metrical temporal lobe atrophy in semantic dementia 
[41] can be used to separate these non-AD dementias 
from AD. Diﬀ  usion imaging and FLAIR are useful in 
identifying both cerebrovascular disease and prion 
disease. MRI is useful in identifying structural contri-
butors to cognitive impairment such as hemorrhage or 
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dementias using sMRI will be particularly helpful when 
therapeutics become readily available.
7. Mechanistic inferences into the disease process
Using sMRI as an independent biomarker of neuro-
degenera  tion aides in understanding relationships 
between cognition and neurodegeneration in AD. Th  is 
has led to insights into disease mechanisms in AD. In the 
model shown in Figure 1 from Jack and colleagues [6], 
the conclusion that neurodegeneration is more proxi-
mately associated with cognitive decline was derived 
from several sMRI studies.
Comparison of structural magnetic resonance 
imaging with other major Alzheimer’s disease 
biomarkers
Th  e major AD biomarkers that are typically considered 
for clinical trials and observational studies are CSF Aβ1-42, 
CSF t-tau, ﬂ  uoro-deoxy-glucose positron emission tomo-
graphy (FDG-PET), Pittsburgh compound B-PET (PIB-
PET), and sMRI. In this section, we will compare sMRI 
with other major AD biomarkers by summarizing studies 
that have compared sMRI with each of these biomarkers 
in the same set of subjects.
Structural magnetic resonance imaging and cerebrospinal 
fl  uid
Low CSF Aβ1-42 levels reﬂ  ect deposition of Aβ in plaques, 
high CSF t-tau reﬂ   ects active axonal and neuronal 
damage, and high p-tau reﬂ  ects phosphorylated-tau and 
has been postulated to more closely mirror NFT forma-
tion. Several CSF and sMRI studies have compared the 
diagnostic and prognostic accuracy of both and have 
attempted to characterize the associations between the 
two biomarkers in the same set of subjects. We have 
summarized these studies in Table 1. Th   e majority of the 
studies have concluded that sMRI and CSF provide 
independent diagnostic information and that the 
combination provides better discrimination of AD than 
either one does alone [42-44]. It has also been shown that 
both biomarkers are good predictors of MCI progression 
to AD [45-47]. However, the associations between both 
of the biomarkers have not been consistent across 
studies. While some studies claim that there is an 
association between CSF biomarkers (speciﬁ  cally t-tau 
and p-tau) and sMRI [42,46,48-54], others have found no 
association between the two [45,55-57]. Th  is could be 
due mainly to the fact that measuring the biomarkers in 
diﬀ  erent study populations (that is, at diﬀ  erent stages of 
the disease) will provide diﬀ  erent answers, and also there 
is a large variability in the methodologies used (that is, 
variability in the assays and sMRI measures ranging from 
visual assessment to automated diagnosis).
Th   e earlier studies concentrated mainly on the 
associations between CSF and sMRI biomarkers, whereas 
the more recent ones have started investigating the 
association between these biomarkers and cognition. 
Studies published on the basis of the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) data have shown that 
sMRI is more closely related to cognition than CSF bio-
markers are [34,43,44,47,55], lending support to the 
model in Figure 1. As suggested by Wahlund and Blennow 
[48], CSF Aβ denotes a speciﬁ  c molecular pathway or 
etiology whereas CSF tau, p-tau, and sMRI may reﬂ  ect 
the disease stage or intensity of AD. However, sMRI 
appears to be a more stable indicator of neuronal loss in 
comparison with the CSF measures. Th   is may be due to 
the fact that brain volume quantiﬁ  cation with sMRI has 
nothing analogous to daily turnover of a soluble protein 
measured using CSF.
Structural magnetic resonance imaging and FDG-PET
Decreased FDG-PET uptake (that is, hypo-metabolism 
on FDG-PET scans) reﬂ   ects metabolic deﬁ   cits due to 
synaptic dysfunction and (probably) tau-mediated 
neuronal injury. sMRI atrophy is seen mainly in the 
medial temporal lobes, whereas FDG uptake decreases 
are seen mainly in the posterior cingulate and parietal 
lobes. Studies that have investigated FDG and MRI in the 
same group of subjects are summarized in Table  2. 
Several studies have compared FDG and sMRI on the 
basis of diagnostic and prognostic accuracy in AD. FDG 
was found to provide slightly better discrimination than 
MRI in [58-62], and a couple of recent studies based on 
ADNI data found that the two have similar performance 
[44,63] and have largely overlapping value for 
discrimination [44]. However, the question of comple-
mentary or overlapping information between FDG and 
sMRI remains to be investigated in a large group of 
subjects in a systematic fashion.
Structural magnetic resonance imaging and PIB-PET
Although there are several amyloid imaging PET tracers 
based on 11C and 18F, the tracer most studied in the ﬁ  eld 
of AD is PIB [64], which we discuss here. PIB-PET scans 
measure the deposition of Aβ in the brain (amyloid load). 
Since the invention of PIB, there has been signiﬁ  cant 
interest in investigating the eﬀ   ect of Aβ plaques as 
measured by PIB [64] on cognition and sMRI. In this 
section, we will discuss studies that have investigated 
both PIB and sMRI in the same group of subjects. Th  ese 
studies are summarized in Table 3. In CN, baseline PIB 
was not associated with longitudinal sMRI changes in the 
preceding years [65] but was strongly related to brain 
atrophy [66,67] and future cognitive decline [66]. Th  e 
majority of studies have found a correlation between 
baseline sMRI and PIB measures [68-70]. In addition, 
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Study   Subjects   Diagnostic measures   Associations 
Schönknecht et al.,   88 AD, 17 CN     In AD, CSF tau was not correlated to MRI.
2003 [57] 
Wahlund and   23 MCI, 24 AD    At baseline, CSF Aβ1-42 was correlated with MRI. During the
Blennow, 2003 [48]      follow-up period, increases in tau and p-tau correlated with 
     ventricular  increase. 
de Leon et al.,   32 stable CN, 13 CN  Accuracy for prediction of CN  Hippocampal volume decrease correlates with P-tau231 increase
2004 [46]  progressed to MCI   progression to MCI:   and Aβ1-42 decrease.
    Baseline: MRI: 78%; CSF: 78% to 89%. 
Hampel et al.,   22 AD    CSF p-tau231 correlated with baseline hippocampus and rates of
2005 [73]      hippocampal atrophy.
Schoonenboom   39 MCI    CSF Aβ1-42 was correlated with MRI and not tau. 
et al., 2005 [74] 
de Leon et al.,   9 CN, 7 MCI  Accuracy for separation of CN  In MCI, longitudinal hippocampal volume decrease correlated
2006 [42]    and MCI: Baseline: MRI: 94%,   with P-tau231 increase and Aβ1-42 decrease.
    CSF: 63% to 88%; MRI + CSF: 94%
    Longitudinal: MRI: 88%; CSF: 73% to 
    88%; MRI + CSF: 94% 
Herukka et al.,   21 MCI, of whom 8    In all MCI, increases in tau and p-tau correlated with a decrease in
2008 [51]  progressed to AD    hippocampal volumes. 
Schoonenboom   32 CN, 61 AD  Odds ratio between AD and CN:   There were no correlations between visual assessment of MRI and
et al., 2008 [56]    MRI: 28; CSF: 57  CSF biomarkers within CN and AD. 
Sluimer et al.,   23 CN, 9 MCI, 47 AD    In AD, CSF p-tau181 had mild association with whole-brain atrophy
2008 [52]      rate. Only MRI was associated with change in cognitive measures. 
Brys et al.,   21 CN, 16 stable MCI,   Accuracy for prediction of MCI  There were no longitudinal correlations between MRI and CSF.
2009 [45]  8 MCI progressed to AD  progression to AD: MRI: 74%; 
    CSF: 70%; MRI + CSF: 84%   
Chou et al.,   80 CN, 80 MCI, 80 AD (ADNI)    CSF Aβ1-42 was correlated with ventricular expansion.
2009 [53]  
Fagan et al.,   69 CN, 29 mild AD    In CN, decrease in CSF Aβ1-42 correlated with brain atrophy. In mild
2009 [54]       AD, increases in CSF t-tau and p-tau181 correlated with brain 
     atrophy.
Henneman et al.,   19 CN, 25 MCI, 31 AD    Baseline CSF p-tau181 was independently associated with
2009 [49]      subsequent disease progression, measured by hippocampal 
     atrophy  rate. 
Leow et al.,   40 CN, 40 MCI, 20 AD (ADNI)    Baseline CSF correlated with temporal atrophy rates over the
2009 [75]      course of 12 months. 
Schuff   et al.,   112 CN, 226 MCI, 96 AD (ADNI)   In MCI, an increase in rates of hippocampal atrophy correlated
2009 [76]      with lower CSF Aβ1-42.
Thomann et al.,   15 CN, 23 MCI (AACD), 16 AD    Increases in CSF t-tau and p-tau181 correlated with cortical atrophy
2009 [50]      in temporal, parietal, and frontal regions.
Vemuri et al.,   109 CN, 192 aMCI,   AUROC separating CN, aMCI, and  Within each clinical group, only MRI correlated with cognition in
2009 [43]  98 AD (ADNI)   AD: MRI: 0.77; CSF: 0.68 to 0.73;   aMCI and AD groups. 
    MRI + CSF: 0.81 
Vemuri et al.,   109 CN, 192 aMCI,   Proportional hazards for predicting  Baseline MRI was a better predictor of subsequent cognitive and
2009 [47]  98 AD (ADNI)  time to conversion from aMCI to   functional decline than baseline CSF was. 
    AD: MRI: 2.6; CSF: 1.7 to 2.0 
Vemuri et al.,   92 CN, 149 MCI,   Sample size required to detect  Longitudinal annual changes were observed only in MRI and not
2010 [34]  71 AD (ADNI)  treatment eff  ects in AD:   in CSF. Change in MRI was associated with change in cognitive
    MRI: 100; CSF >105. measures. 
Walhovd et al.,   42 CN, 73 MCI,   Accuracy for baseline separation  In MCIs, only baseline MRI and FDG were correlated to (or
2010 [44]  38 AD (ADNI)  of CN and AD: MRI: 85%;   predictive of) future clinical decline during 2 years. 
    CSF: 81.2%; CSF + MRI: 88.8%  
Fjell et al.,   71 CN    Below a certain threshold, baseline CSF Aβ1-42 correlated with
2010 [77]      ventricular increase and volumetric brain decrease over the 
      course of 1 year. 
Fjell et al.,   Baseline: 105 CN, 175 MCI,     In MCI and AD, baseline CSF measures were not related to
2010 [55]  90 AD (ADNI)     baseline MRI but were related to longitudinal atrophy. Baseline 
      MRI predicted change in cognition better than CSF did. 
Search terms were ‘MRI and CSF and Alzheimer’s’. AACD, age-associated cognitive decline; AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; 
aMCI, amnestic mild cognitive impairment; AUROC, area under the receiver operating characteristic; CN, cognitively normal; CSF, cerebrospinal fl  uid; FDG, fl  uoro-
deoxy-glucose; MCI, mild cognitive impairment; MRI, magnetic resonance imaging.
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changes are much more pronounced on sMRI and that 
longitudinal change in PIB is minimal [1,71]. All of this 
evidence has led to our understanding that Aβ deposition 
measured by PIB is an upstream process whereas 
neurodegeneration is a downstream process that is 
probably initiated by Aβ deposition and is more closely 
related to cognitive decline [1,2].
Conclusions and future directions in structural 
magnetic resonance imaging
Given that the clinical assessment is unlikely to exactly 
match ﬁ   ndings at autopsy in every subject, in vivo 
imaging measures (such as sMRI) that reﬂ  ect  disease 
stage and intensity would be extremely useful. Th  e  value 
added to clinical assessment by MRI is that it is an 
independent non-invasive measure of neuronal loss and 
thus provides a supplementary measure based only on 
anatomy; by contrast, clinical diagnosis is done on the 
basis of clinical examination and neuropsychological 
tests. Numerous studies now show that sMRI is a stable 
biomarker of AD progression. Publications on sMRI data 
from multicenter studies such as ADNI have also 
provided evidence that the combination of sMRI scans 
from multicenter studies is possible without much 
penalty [72]. In addition to being of diagnostic and prog-
nostic value, sMRI can play multiple roles, as described 
in this review.
Table 2. Summary of combined magnetic resonance imaging and fl  uoro-deoxy-glucose studies in Alzheimer’s disease
Study   Subjects   Diagnostic measures   Associations 
Yamaguchi et al.,   13 AD, 13 CN    Hippocampal volume and mean cortical cerebral glucose
1997 [78]      metabolic rates of the temporal lobe, temporo-parieto-occipital, 
      and frontal regions were correlated. 
De Santi et al.,   11 CN, 15 MCI, 12 AD  Accuracy for separation of MCI  FDG and MRI measures in hippocampal formation best
2001 [59]    and CN: MRI: 73%; FDG: 73% to 85%  characterize MCI, and additional neocortical damage best
    AD and CN: MRI: 83%; FDG: 100%   characterizes AD. 
Ishii et al.,   30 CN, 30 very mild AD    VBM: decrease in MRI in medial temporal lobes and decrease in
2005 [79]      FDG in posterior cingulate and parietal lobule
Kawachi et al.,   60 CN, 30 very mild AD,   Accuracy for separating very mild  VBM: decrease in MRI in bilateral amygdala/hippocampus
2006 [60]  32 mild AD   AD and CN: FDG: 89%; MRI: 83%;   complex and decrease in FDG in bilateral posterior cingulate and
    MRI + FDG: 94%  parietotemporal area
Mosconi et al.,   7 CN, 7 asymptomatic  Accuracy for separation of both  FDG showed signifi  cant decrease but little sMRI change in
2006 [58]  at-risk FAD   groups: MRI: 43% to 86%;   asymptomatic subjects.
    FDG: 50% to 100%   
Ishii et al.,   20 very mild AD,   Accuracy for separation of DLB and  Both MRI and FDG had a hippocampal decrease due to AD. 
2007 [62]  20 DLB, 20 CN   AD: MRI: 62% to 80%; FDG: 66% to 87%  
Matsunari et al.,   Group 1: 40 CN, 27 AD  Accuracy for diff  erent comparisons:   VBM: decrease in MRI in hippocampal complex and decrease in
2007 [61]  Group 2 (early- and   MRI: 74% to 92%; FDG: 92% to 100%  FDG in posterior cingulate and parietotemporal area
  late-onset): 50 CN, 34 AD    
Samuraki et al.,   73 CN, 39 AD    VBM: FDG uptake was preserved in the medial temporal lobe
2007 [80]      before as well as after correction with MRI. 
Chetelat et al.,   15 CN, 18 mild AD    FDG hypometabolism exceeds MRI atrophy in the posterior
2008 [81]      cingulate-precuneus, orbitofrontal, inferior temporo-parietal, 
      parahippocampal, angular, and fusiform areas. Similar degrees of 
      atrophy and hypometabolism were observed in the 
     hippocampus.
Hinrichs et al.,   CN and AD subjects from   AUROC for discrimination of AD 
2009 [63]  ADNI: MRI: 183, FDG: 149   and CN: MRI: 0.88; FDG: 0.87 
Walhovd et al.,   22 CN, 44 MCI    MRI predicted diagnostic groups for most regions of interest, but
2009 [82]      PET did not, except a trend for the precuneus metabolism. 
Yuan et al.,   Meta-analysis of 24 MCI  Odds ratio of predicting MCI  FDG was better than MRI in predicting conversion of MCI to AD. 
2009 [30]  studies (1112 subjects)  conversion to AD: MRI: 10.6; FDG: 40.1  
Morbelli et al.,   12 CN, 11 stable MCI,     MCI converters showed MRI changes in left parahippocampus
2010 [83]  9 MCI who progressed to AD     and both thalami, whereas FDG showed MRI changes in left PCC, 
      precuneus, superior parietal lobule. 
Walhovd et al.,   42 CN, 73 MCI,   Accuracy for baseline separation  MRI and FDG were largely overlapping in value for discrimination.
2010 [44]  38 AD (ADNI)  of AD and CN: MRI: 85%; FDG: 82.5%  
Search terms were ‘MRI and FDG and Alzheimer’s’. AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; AUROC, area under the receiver 
operating characteristic; CN, cognitively normal; DLB, dementia with Lewy bodies; FAD, familial Alzheimer’s disease; FDG, fl  uoro-deoxy-glucose; MCI, mild cognitive 
impairment; MRI, magnetic resonance imaging; PCC, posterior cingulate cortex; PET, positron emission tomography; VBM, voxel-based morphometry.
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Page 7 of 10Th  ree future directions still need to be thoroughly 
investi  gated. (a) Th   e development of robust, validated, and 
automated techniques for extracting disease-speciﬁ  c 
information from cross-sectional and serial sMRIs needs 
to be investigated. (b) Because the majority of the studies 
discussed here were done on highly screened popula  tions, 
it is important to validate the generalizability of sMRI as a 
biomarker in clinically based cohorts in which the presence 
of multiple pathologies and disorders is a norm rather than 
an exception. (c) How these sMRI measures can be 
integrated with other clinical measures, CSF, and PET 
biomarkers to be of clinical use needs to be investigated.
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